VivoSeq
Metabolic & Endocrine

Pituitary Gland Disease

2

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Pituitary Gland Disease is an early-stage landscape with 2 programs across 1 company. The most active players are EMD Serono. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Somatropin

EMD Serono

Phase 1
No programs
Phase 2
No programs
Phase 31

Pegvisomant

Pharmacia and Upjohn

Approved
No programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)